Skip to content

Evolocumab for ImproVing FunctiOnal Outcomes in ThromboLyzed Patients with Acute Ischemic Stroke without Large VEssel Occlusion: A Prospective, Multicenter, Randomized Controlled Trial (EVOLVE-Stroke I)

Evolocumab for ImproVing FunctiOnal Outcomes in ThromboLyzed Patients with Acute Ischemic Stroke without Large VEssel Occlusion: A Prospective, Multicenter, Randomized Controlled Trial (EVOLVE-Stroke I)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125072
Enrollment
Unknown
Registered
2026-05-21
Start date
2026-05-21
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Interventions

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years; 2. Acute ischemic stroke, receiving intravenous thrombolysis within 4.5 hours of onset; 3. Baseline NIHSS score 5-15, with at least one limb NIHSS motor item score >= 2; 4. Pre-stroke mRS 0-1; 5. Non-large vessel occlusion (CTA/MRA excludes internal carotid artery, M1 segment of middle cerebral artery, basilar artery occlusion); 6. Patient or their legally authorized representative provides informed consent.

Exclusion criteria

Exclusion criteria: 1. Planned endovascular treatment; 2. Intracranial hemorrhage or hemorrhagic transformation; 3. Received PCSK9 monoclonal antibody therapy within 1 month before enrollment, or PCSK9 siRNA therapy within 6 months before enrollment; 4. Patients allergic to PCSK9 inhibitors; 5. Severe liver dysfunction (ALT or AST >3 times the upper limit of normal); 6. Severe renal dysfunction (eGFR <30 ml/min/1.73m^2); 7. Pregnant or breastfeeding women; 8. Expected life expectancy <6 months; 9. Currently participating in other interventional clinical trials.

Design outcomes

Primary

MeasureTime frame
Proportion of patients with mRS scores of 0–2 (functional independence) at 90 days.;

Secondary

MeasureTime frame
Proportion of patients with mRS scores of 0–1 (favorable functional outcome) at 90 days.;Recurrent stroke (ischemic or hemorrhagic) at 90 days;Change in low-density lipoprotein cholesterol (LDL-C) levels from baseline to Day 7, Day 30, and Day 90;Infarct volume assessed by MRI or CT at 24 to 72 hours;Change in the National Institutes of Health Stroke Scale (NIHSS) score from baseline to Day 5-7 or discharge (whichever occurs first);Rate of LDL-C target achievement at 90 days;All-cause mortality at 90 days;Incidence of symptomatic intracranial hemorrhage (sICH) within 24 to 48 hours;Distribution of mRS scores at 90 days;

Countries

China

Contacts

Public ContactBo Hu

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

hubohust@163.com+86 137 0711 4863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026